Transcriptomics

Dataset Information

0

SRC1 gene regulation in endocrine resistant breast cancer cells


ABSTRACT: The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the development of a steroid independent tumour. The p160 steroid coactivator protein SRC-1, through interactions with developmental proteins and other non-steroidal transcription factors drives this tumour adaptability. Here, using discovery studies we identify ADAM22, a non-protease member of the ADAMs family, as a direct target of SRC-1, independent of estrogen receptor(ER). Molecular, cellular, in vivo and clinical studies confirmed SRC-1 as a regulator of ADAM22 and established a role for ADAM22 in endocrine resistant tumour progression. ADAM22 has the potential to act as a therapeutic drug target and a companion predictive biomarker in the treatment of endocrine resistant breast cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE28645 | GEO | 2012/01/11

SECONDARY ACCESSION(S): PRJNA138957

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2012-01-11 | E-GEOD-28645 | biostudies-arrayexpress
2011-11-01 | E-GEOD-28987 | biostudies-arrayexpress
2011-11-01 | GSE28987 | GEO
2018-06-04 | GSE99647 | GEO
2018-06-04 | GSE99648 | GEO
2014-01-14 | E-GEOD-54027 | biostudies-arrayexpress
2014-01-14 | GSE54027 | GEO
2023-05-16 | GSE176534 | GEO
2010-05-16 | E-GEOD-17775 | biostudies-arrayexpress
2023-06-27 | MTBLS3342 | MetaboLights